Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine During 26 Weeks of Therapy.
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2010
At a glance
- Drugs Insulin glargine; Insulin glulisine
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 03 Nov 2007 New trial record.